The Atopic Keratoconjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Atopic Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Atopic Keratoconjunctivitis. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Atopic Keratoconjunctivitis and features dormant and discontinued products.

GlobalData tracks five drugs in development for Atopic Keratoconjunctivitis by five companies/universities/institutes. The top development phase for Atopic Keratoconjunctivitis is preclinical with two drugs in that stage. The Atopic Keratoconjunctivitis pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Atopic Keratoconjunctivitis pipeline products market are: Viatris, Allakos and Regeneron Pharmaceuticals.

The key targets in the Atopic Keratoconjunctivitis pipeline products market include Cells Expressing Sialic Acid Binding Ig Like Lectin 8 (Sialoadhesin Family Member 2 or SIGLEC8), Amiloride Sensitive Amine Oxidase [Copper Containing] (Amiloride Binding Protein 1 or Kidney Amine Oxidase or Diamine Oxidase or Amine Oxidase Copper Domain Containing Protein 1 or Histaminase or AOC1 or EC, and Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R).

The key mechanisms of action in the Atopic Keratoconjunctivitis pipeline product include Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist with one drug in Phase II. The Atopic Keratoconjunctivitis pipeline products include four routes of administration with the top ROA being Intravenous and two key molecule types in the Atopic Keratoconjunctivitis pipeline products market including Monoclonal Antibody, and Gene Therapy.

Atopic Keratoconjunctivitis overview

Atopic keratoconjunctivitis (AKC) is chronic allergic disease of eye. It is caused by atopy, a genetic condition that causes the immune system to produce more antibodies than normal in response to allergens. Symptoms include sensitivity to light, itching, burning, tearing, and red and hardened eyelids. AKC is usually diagnosed through clinical examination and a medical and family history, although a conjunctival biopsy may be helpful. Cold compresses and saline irrigation can lower the elevated tear pH. Only in severe cases should topical steroid therapy be used.

For a complete picture of Atopic Keratoconjunctivitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.